Revisiting the Obesity Paradox in Metabolic Dysfunction-Associated Steatotic Liver Disease: Longitudinal Trajectory Analysis Reveals Time-Varying Mortality Risks
Clinical Gastroenterology and Hepatology · 2026-09 · 24 (9) · 2486-2498
DOI: 10.1016/j.cgh.2026.01.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-09. Verfasst von Zhen Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Sha…. Hauptthemen laut MEDLINE: Obesity, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Health Commission, National Key Research and Development Program of China.
Abstract (Originalsprache)
BACKGROUND & AIMS: Obesity is a key driver of metabolic dysfunction-associated steatotic liver disease (MASLD). Paradoxically, obese patients with MASLD often exhibit better survival than their nonobese counterparts. This study investigates the "obesity-survival paradox" using longitudinal body mass index (BMI) data. METHODS: We analyzed 3 large population-based MASLD cohorts, including National Health and Nutrition Examination Survey (NHANES) III (n = 2190), NHANES 1999-2018 (n = 5210), and UK Biobank (n = 8962). We assessed the dose-response associations of BMI at different stages of adulthood/disease with mortality using multivariable-adjusted restricted cubic spline models. Latent class trajectory modeling identified distinct clusters of long-term BMI patterns. RESULTS: BMI above 30 kg/m2 in mid-to-late adulthood or after MASLD diagnosis was associated with decreased overall mortality (P < .001), indicating an obesity-survival benefit. Conversely, higher early-adulthood BMI was associated with increased mortality (P < .001). Pre-diagnostic BMI displayed U-shaped and J-shaped associations with all-cause and cancer-specific mortality, respectively. Trajectory analyses indicated that the cluster with persistent nonobesity throughout adulthood had a low overall mortality risk, whereas persistent obesity (hazard ratio, 1.79; 95% confidence interval, 1.10-2.89) and rapid BMI increase (hazard ratio, 1.93; 95% confidence interval, 1.03-3.64) were associated with significantly higher mortality. Clusters with earlier obesity onset tended toward higher mortality. Among clusters exposed to obesity before age 40, BMI had a tendency to decline during later life, and such BMI declines across adulthood were associated with increased mortality (P < .001). CONCLUSIONS: This study demonstrates that the association between obesity and MASLD outcomes is heterogeneous and depends on the timing of obesity exposure. Long-term BMI trajectory analysis suggests that obesity does not confer a survival advantage in MASLD, whereas maintaining nonobese status throughout adulthood is associated with lower overall mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Hengyang Medical School, University of South China, Hengyang, China.
- Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China. Electronic address: dengxuan@huashan.org.cn.
- Department of Endocrinology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: libo@xinhuamed.com.cn.
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Health Commission
- National Key Research and Development Program of China
Zitieren
APA
Sun, Z., Li, J., Yu, X., Jiang, Y., Zheng, J., Ouyang, Y., Guan, M., Deng, X., Li, B., & Jin, H. (2026). Revisiting the Obesity Paradox in Metabolic Dysfunction-Associated Steatotic Liver Disease: Longitudinal Trajectory Analysis Reveals Time-Varying Mortality Risks. Clinical Gastroenterology and Hepatology, 24(9), 2486-2498. https://doi.org/10.1016/j.cgh.2026.01.033
Vancouver
Sun Z, Li J, Yu X, Jiang Y, Zheng J, Ouyang Y, et al. Revisiting the Obesity Paradox in Metabolic Dysfunction-Associated Steatotic Liver Disease: Longitudinal Trajectory Analysis Reveals Time-Varying Mortality Risks. Clinical Gastroenterology and Hepatology. 2026;24(9):2486-2498. doi:10.1016/j.cgh.2026.01.033
BibTeX
@article{Sun2026,
author = {Sun, Zhen and Li, Jinhao and Yu, Xuefei and Jiang, Yuchen and Zheng, Jiaojiao and Ouyang, Yuan and Guan, Ming and Deng, Xuan and Li, Bo and Jin, Haojie},
title = {Revisiting the Obesity Paradox in Metabolic Dysfunction-Associated Steatotic Liver Disease: Longitudinal Trajectory Analysis Reveals Time-Varying Mortality Risks},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {9},
pages = {2486--2498},
doi = {10.1016/j.cgh.2026.01.033}
}
EUVIMED